alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › proteomic-biomarkers

proteomic-biomarkers

3 studies tagged proteomic-biomarkers, dated 2012-06-26 to 2021-01-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Recent Evidence in Epigenomics and Proteomics Biomarkers for Early and Minimally Invasive Diagnosis of Alzheimer's and Parkinson's Diseases 2021-01-01
  2. Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology 2015-11-16
  3. Blood and plasma-based proteomic biomarker research in Alzheimer's disease 2012-06-26

Studies

3 studies carry this tag.

Date range

2012 to 2021

Top journals

  • Current neuropharmacology 1
  • Frontiers in neurology 1
  • Progress in neurobiology 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Recent Evidence in Epigenomics and Proteomics Biomarkers for Early and Minimally Invasive Diagnosis of Alzheimer's and Parkinson's Diseases

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Current neuropharmacology 2021-01-01 TREM2 and immune genetics

    In general, there is a common lack of clinical validation of these potential biomarkers because of which its use in clinical practice is still limited.

  2. Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Frontiers in neurology 2015-11-16 Genetics

    The complexity of Alzheimer's disease (AD) and its long prodromal phase poses challenges for early diagnosis and yet allows for the possibility of the development of disease modifying treatments for secondary prevention.

  3. Blood and plasma-based proteomic biomarker research in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Progress in neurobiology 2012-06-26 Genetics

    Alzheimer's disease (AD) is the most important cause of dementia in the elderly.

All topic tags with their study counts